2,6-diamino-3-methoxy-5-nitropyridine | 127356-36-9

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 2,6-diamino-3-methoxy-5-nitropyridine
• 英文别名: 3-methoxy-5-nitropyridine-2,6-diamine
• CAS: 127356-36-9
• 化学式: C₆H₈N₄O₃
• 分子量: 184.155
• InChiKey: ZICNROTYASJXDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,6-diamino-3-methoxy-5-nitropyridine 在 铁粉 、 potassium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 di-tert-butyl (3-amino-5-methoxypyridine-2,6-diyl)dicarbamate
  参考文献：
  名称：

  Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists

  摘要：

  A knowledge-based library of 2,3-dichlorophenylsulfonyl derivatives of commercially available aryl amines was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. Hits were required to be more potent than an existing indazole series, have better physicochemical properties (clogP <3.5, chrom logD₇.₄ <5.3 and CLND solubility >116 μg/mL), and be stable to acid and light. The benzimidazol-2-one core was identified as a hit suitable for further investigation. Substitution at N1 with small alkyl groups was tolerated; however, these analogues were inactive in the whole blood assay (pA₂ <5). Azabenzimidazolone analogues were all found to be active, with compound 38 exhibiting whole blood activity of 6.1, low molecular weight (389) and chrom logD₇.₄ (2.4), high LE (0.43), and solubility (152 μg/mL). In addition, 38 had human serum albumin binding of around 93% and met all the criteria for progression to lead optimisation.

  DOI：

  10.1016/j.bmc.2014.05.021
• 作为产物：
  描述：

  2,6-二溴-3-甲氧基-5-硝基吡啶 在 ammonium hydroxide 作用下， 反应 16.0h， 以85%的产率得到2,6-diamino-3-methoxy-5-nitropyridine
  参考文献：
  名称：

  变力性的“ A”环取代的舒马唑和异唑类似物。

  摘要：

  已经制备了一系列“ A”环取代的舒马唑和异咪唑类似物，并评价为正性肌力药。测量所选化合物的pKA，质子化位点和log P值，并计算其电子性能。在正性肌力活动与pKA，质子化位点或log P值之间未发现简单的相关性。但是，体外变力性确实与“ B”环咪唑氮原子的电荷密度相关。舒马唑的6-位似乎对取代基具有最高的耐受性，6-氨基衍生物7比舒马唑本身更有效。4-甲氧基异唑13具有与异唑相当的体内正性肌力。

  DOI：

  10.1021/jm00170a030

文献信息

• Inotropic 'A' ring substituted sulmazole and isomazole analogs
  作者：Paul Barraclough、James W. Black、David Cambridge、David Collard、David Firmin、V. Paul Gerskowitch、Robert C. Glen、Heather Giles、Alan P. Hill

  DOI：10.1021/jm00170a030

  日期：1990.8

  A series of "A" ring substituted sulmazole and isomazole analogues have been prepared and evaluated as inotropic agents. pKA's, protonation sites, and log P values were measured for selected compounds and their electronic properties were calculated. No simple correlation between inotropic activity and pKA, protonation site, or log P value was observed. However, in vitro inotropism did correlate with

  已经制备了一系列“ A”环取代的舒马唑和异咪唑类似物，并评价为正性肌力药。测量所选化合物的pKA，质子化位点和log P值，并计算其电子性能。在正性肌力活动与pKA，质子化位点或log P值之间未发现简单的相关性。但是，体外变力性确实与“ B”环咪唑氮原子的电荷密度相关。舒马唑的6-位似乎对取代基具有最高的耐受性，6-氨基衍生物7比舒马唑本身更有效。4-甲氧基异唑13具有与异唑相当的体内正性肌力。
• BARRACLOUGH, PAUL;BLACK, JAMES W.;CAMBRIDGE, DAVID;COLLARD, DAVID;FIRMIN,+, J. MED. CHEM., 33,(1990) N, C. 2231-2239
  作者：BARRACLOUGH, PAUL、BLACK, JAMES W.、CAMBRIDGE, DAVID、COLLARD, DAVID、FIRMIN,+

  DOI：——

  日期：——
• Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists
  作者：Afjal H. Miah、Hossay Abas、Malcolm Begg、Benjamin J. Marsh、Daniel E. O’Flynn、Alison J. Ford、Jonathan M. Percy、Panayiotis A. Procopiou、Steve A. Richards、Sally-Anne Rumley

  DOI：10.1016/j.bmc.2014.05.021

  日期：2014.8

  A knowledge-based library of 2,3-dichlorophenylsulfonyl derivatives of commercially available aryl amines was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. Hits were required to be more potent than an existing indazole series, have better physicochemical properties (clogP <3.5, chrom logD₇.₄ <5.3 and CLND solubility >116 μg/mL), and be stable to acid and light. The benzimidazol-2-one core was identified as a hit suitable for further investigation. Substitution at N1 with small alkyl groups was tolerated; however, these analogues were inactive in the whole blood assay (pA₂ <5). Azabenzimidazolone analogues were all found to be active, with compound 38 exhibiting whole blood activity of 6.1, low molecular weight (389) and chrom logD₇.₄ (2.4), high LE (0.43), and solubility (152 μg/mL). In addition, 38 had human serum albumin binding of around 93% and met all the criteria for progression to lead optimisation.